Maternal death · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in maternal death compared with control (moderate certainty).
1 finding from 1 review
Infant death (up to 175 days) · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in infant death (up to 175 days) compared with control (moderate certainty).
1 finding from 1 review
Perinatal death (stillbirth + death in first week of life) · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in perinatal death (stillbirth + death in first week of life) compared with control (moderate certainty).
1 finding from 1 review
Any respiratory illness in women · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in any respiratory illness in women compared with control (high certainty).
1 finding from 1 review
Any respiratory illness in infants · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in any respiratory illness in infants compared with control (high certainty).
1 finding from 1 review
Maternal hospitalisation for any infection · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in maternal hospitalisation for any infection compared with control (moderate certainty).
1 finding from 1 review
Neonatal hospitalisation due to sepsis within 28 days of birth · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in neonatal hospitalisation due to sepsis within 28 days of birth compared with control (moderate certainty).
1 finding from 1 review
Neonatal tetanus deaths ‐ 1 dose · women aged between 13 and 45 years.
Tetanus toxoid showed no clear difference in neonatal tetanus deaths ‐ 1 dose compared with influenza vaccine (low certainty).
1 finding from 1 review
Neonatal tetanus deaths ‐ 2 or 3 doses · women aged between 13 and 45 years.
Tetanus toxoid probably leads to lower neonatal tetanus deaths ‐ 2 or 3 doses compared with influenza vaccine (moderate certainty).
1 finding from 1 review
All causes of deaths ‐ 1 dose · women aged between 13 and 45 years.
Tetanus toxoid showed no clear difference in all causes of deaths ‐ 1 dose compared with influenza vaccine (low certainty).
1 finding from 1 review
All causes of deaths ‐ 2 or 3 doses · women aged between 13 and 45 years.
Tetanus toxoid probably leads to lower all causes of deaths ‐ 2 or 3 doses compared with influenza vaccine (moderate certainty).
1 finding from 1 review
Neonatal tetanus cases ‐ Any dose · women aged between 13 and 45 years.
Tetanus toxoid probably leads to lower neonatal tetanus cases ‐ Any dose compared with influenza vaccine (moderate certainty).
1 finding from 1 review